Last reviewed · How we verify
Lymphoseek
Lymphoseek is a marketed diagnostic aid developed by Eben Rosenthal, currently holding a niche position in the diagnostic imaging market. Its key strength lies in its unique mechanism of action, which differentiates it from other diagnostic tools. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Lymphoseek |
|---|---|
| Also known as | 99mTc-Diethylenetriamine Pentaacetic Acid-Mannosyl-Dextran, 99mTc-DTPA-Mannosyl-Dextran, Technetium Tc 99m-labeled Tilmanocept, technetium Tc 99m tilmanocept, Tc-99m Tilmanocept (Lymphoseek) |
| Sponsor | Eben Rosenthal |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Diagnostic aid
Common side effects
- Injection site irritation
- Injection site pain
Key clinical trials
- Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial (PHASE2)
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) (PHASE1)
- Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA (PHASE3)
- Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept (PHASE2)
- Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA (PHASE2)
- Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH (PHASE1)
- Lymphatic Mapping Of Oropharyngeal Cancer (NA)
- A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lymphoseek CI brief — competitive landscape report
- Lymphoseek updates RSS · CI watch RSS
- Eben Rosenthal portfolio CI